Logo Scientific Seminars

The 2022 Digital Learning Journey on Hypertension

15 May 2022

Hypertension is one of the leading causes of death worldwide, and the contribution of high blood pressure to morbidity and mortality has remained stable in the last decade, despite considerable advances in treatment of the disease.

In 2018, the European Society of Hypertension / European Society of Cardiology Hypertension Guidelines included elevated heart rate as a factor influencing cardiovascular risk in patients with hypertension. Elevated heart rate is a simple, non-invasive measure of sympathetic nervous system activity, and including this measure in the Guidelines acknowledges the crucial role that sympathetic nervous system overactivity plays in the pathogenesis of cardiovascular disease.

When treatment to control hypertension is unsuccessful, patients can develop heart failure, which is a long-term chronic condition. Beta-blockers are recommended for all patients with stable, symptomatic heart failure to reduce the risk of heart failure hospitalization and death by both the American Heart Association/American College of Cardiology and the European Society of Cardiology guidelines. Newer agents have also been shown to be of value, especially as the heart failure progresses, however, heart failure management remains a challenge for the healthcare community. Discussion of the use of standard, established therapies for heart failure, in combination with newer agents that have just completed clinical trials, particularly for heart failure with preserved ejection fraction (HFpEF), provides insight into safe and effective practice.

This comprehensive learning journey on cardiovascular disease and hypertension has been designed by Scientific Seminars International Foundation to bring together the latest innovations in cardiovascular disease prevention for patients with arterial hypertension, increasing participant knowledge in this area, introducing recent research into cardiovascular risk factors, and discussing the best approach for clinical management of complex hypertensive patients in daily practice.


The video interview will have subtitles and the live webinar will have a simultaneous translation into both Russian and Chinese (Mandarin)

On completion of this educational activity, learners should be able to:

  1. Identify the role of increased sympathetic nervous system activity in the pathogenesis of hypertension and hypertension-related disease
  1. Describe how to combine old and new drugs for the treatment of hypertensive patients with HFpEF
  2. List novel aspects of the pathophysiology of hypertension and hypertension-related cardiovascular disease
  3. Discuss the choice of appropriate therapy to treat increased sympathetic nervous system activity

Cardiologists, general practitioners and internists

This learning journey is a structured e-learning educational program comprising:

  • Video Interview: How to manage patients with HFpEF

LAUNCH: 15 May 2022

  • Congress Report: ESH 2022, June 17-20, Athens, Greece

LAUNCH: 31 July 2022

  • Live Webinar: What is new in cardiovascular medicine?

LAUNCH: 15 September 2022

  • Video Lecture: SNS activity and cardiovascular risk

LAUNCH: 15 November 2022

Share on social


Cífková Renata
Cleland John
Pathak Atul
Taddei Stefano
Tadic Marijana
Tsioufis Konstantinos

Michela Fiuzzi | Senior Progamme Manager | michela.fiuzzi@scientificseminars.com

This educational program is made possible thanks to an independent educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

Scientific Seminars Foundation
My Agile Privacy
This website uses technical and profiling cookies. Clicking on "Accept" authorises all profiling cookies. Clicking on "Refuse" or the X will refuse all profiling cookies. By clicking on "Customise" you can select which profiling cookies to activate.
Warning: some page functionalities could not work due to your privacy choices